Research Papers:

Synthesis and evaluation of anthranilamide-based derivatives as FXa inhibitors

Changjiang Huang, Wenzhi Wang, Yao Li, Shijun Zhang, Fancui Meng, Weiren Xu, Jing Yuan _ and Ligong Chen

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:37186-37199. https://doi.org/10.18632/oncotarget.16427

Metrics: PDF 1977 views  |   HTML 2042 views  |   ?  


Changjiang Huang1,2, Wenzhi Wang3, Yao Li2, Shijun Zhang2, Fancui Meng2, Weiren Xu2, Jing Yuan2, Ligong Chen1,4,5

1School of Chemical Engineering and Technology, Tianjin University, Tianjin, China

2Tianjin Key Laboratory of Molecular Design and Drug Discovery, Tianjin Institute of Pharmaceutical Research, Tianjin, China

3School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang, China

4Collaborative Innovation Center of Chemical Science and Engineering, Tianjin, China

5Tianjin Engineering Research Center of Functional Fine Chemicals, Tianjin, China

Correspondence to:

Jing Yuan, email: [email protected]

Ligong Chen, email: [email protected]

Keywords: thrombosis, thromboembolic diseases, anticoagulants, factor Xa inhibitors, thrombin and docking simulation

Received: November 23, 2016     Accepted: March 10, 2017     Published: March 21, 2017


Factor Xa (FXa) plays a significant role in the blood coagulation cascade and is a promising target for anticoagulation drugs. Three oral FXa inhibitors have been approved by FDA for treating thrombotic diseases. In this study, 43 novel compounds were synthesized anthranilamide-based FXa inhibitors aiming to ameliorate the toxicity of traditional FXa inhibitors in clinic. The data indicated that the compounds 6a, 6a-b, 6a-e, 6k, 6k-a and 6k-b showed remarkable FXa inhibitory activity and excellent selectivity over thrombin in vitro. Selected compounds also exhibited anticoagulant activities in vitro consequently and were potent novel anti-coagulators in further.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16427